147 related articles for article (PubMed ID: 23933257)
1. Integrating genomic, epigenomic, and transcriptomic features reveals modular signatures underlying poor prognosis in ovarian cancer.
Zhang W; Liu Y; Sun N; Wang D; Boyd-Kirkup J; Dou X; Han JD
Cell Rep; 2013 Aug; 4(3):542-53. PubMed ID: 23933257
[TBL] [Abstract][Full Text] [Related]
2. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome.
Tothill RW; Tinker AV; George J; Brown R; Fox SB; Lade S; Johnson DS; Trivett MK; Etemadmoghadam D; Locandro B; Traficante N; Fereday S; Hung JA; Chiew YE; Haviv I; ; Gertig D; DeFazio A; Bowtell DD
Clin Cancer Res; 2008 Aug; 14(16):5198-208. PubMed ID: 18698038
[TBL] [Abstract][Full Text] [Related]
3. Genomic and Epigenomic Signatures in Ovarian Cancer Associated with Resensitization to Platinum Drugs.
Fang F; Cardenas H; Huang H; Jiang G; Perkins SM; Zhang C; Keer HN; Liu Y; Nephew KP; Matei D
Cancer Res; 2018 Feb; 78(3):631-644. PubMed ID: 29229600
[TBL] [Abstract][Full Text] [Related]
4. An integrated genomic-based approach to individualized treatment of patients with advanced-stage ovarian cancer.
Dressman HK; Berchuck A; Chan G; Zhai J; Bild A; Sayer R; Cragun J; Clarke J; Whitaker RS; Li L; Gray J; Marks J; Ginsburg GS; Potti A; West M; Nevins JR; Lancaster JM
J Clin Oncol; 2007 Feb; 25(5):517-25. PubMed ID: 17290060
[TBL] [Abstract][Full Text] [Related]
5. MethCNA: a database for integrating genomic and epigenomic data in human cancer.
Deng G; Yang J; Zhang Q; Xiao ZX; Cai H
BMC Genomics; 2018 Feb; 19(1):138. PubMed ID: 29433427
[TBL] [Abstract][Full Text] [Related]
6. Network-based survival analysis reveals subnetwork signatures for predicting outcomes of ovarian cancer treatment.
Zhang W; Ota T; Shridhar V; Chien J; Wu B; Kuang R
PLoS Comput Biol; 2013; 9(3):e1002975. PubMed ID: 23555212
[TBL] [Abstract][Full Text] [Related]
7. Identification of ovarian cancer subtype-specific network modules and candidate drivers through an integrative genomics approach.
Zhang D; Chen P; Zheng CH; Xia J
Oncotarget; 2016 Jan; 7(4):4298-309. PubMed ID: 26735889
[TBL] [Abstract][Full Text] [Related]
8. Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer.
Zorn KK; Bonome T; Gangi L; Chandramouli GV; Awtrey CS; Gardner GJ; Barrett JC; Boyd J; Birrer MJ
Clin Cancer Res; 2005 Sep; 11(18):6422-30. PubMed ID: 16166416
[TBL] [Abstract][Full Text] [Related]
9. Genomics and epigenomics of clear cell renal cell carcinoma: recent developments and potential applications.
Rydzanicz M; Wrzesiński T; Bluyssen HA; Wesoły J
Cancer Lett; 2013 Dec; 341(2):111-26. PubMed ID: 23933176
[TBL] [Abstract][Full Text] [Related]
10. Gene expression in ovarian cancer reflects both morphology and biological behavior, distinguishing clear cell from other poor-prognosis ovarian carcinomas.
Schwartz DR; Kardia SL; Shedden KA; Kuick R; Michailidis G; Taylor JM; Misek DE; Wu R; Zhai Y; Darrah DM; Reed H; Ellenson LH; Giordano TJ; Fearon ER; Hanash SM; Cho KR
Cancer Res; 2002 Aug; 62(16):4722-9. PubMed ID: 12183431
[TBL] [Abstract][Full Text] [Related]
11. Pathway Relevance Ranking for Tumor Samples through Network-Based Data Integration.
Verbeke LP; Van den Eynden J; Fierro AC; Demeester P; Fostier J; Marchal K
PLoS One; 2015; 10(7):e0133503. PubMed ID: 26217958
[TBL] [Abstract][Full Text] [Related]
12. High-risk ovarian cancer based on 126-gene expression signature is uniquely characterized by downregulation of antigen presentation pathway.
Yoshihara K; Tsunoda T; Shigemizu D; Fujiwara H; Hatae M; Fujiwara H; Masuzaki H; Katabuchi H; Kawakami Y; Okamoto A; Nogawa T; Matsumura N; Udagawa Y; Saito T; Itamochi H; Takano M; Miyagi E; Sudo T; Ushijima K; Iwase H; Seki H; Terao Y; Enomoto T; Mikami M; Akazawa K; Tsuda H; Moriya T; Tajima A; Inoue I; Tanaka K;
Clin Cancer Res; 2012 Mar; 18(5):1374-85. PubMed ID: 22241791
[TBL] [Abstract][Full Text] [Related]
13. Integrated multi-omics analysis of genomics, epigenomics, and transcriptomics in ovarian carcinoma.
Zheng M; Hu Y; Gou R; Wang J; Nie X; Li X; Liu Q; Liu J; Lin B
Aging (Albany NY); 2019 Jun; 11(12):4198-4215. PubMed ID: 31257224
[TBL] [Abstract][Full Text] [Related]
14. Identification of molecular subtypes of gastric cancer with different responses to PI3-kinase inhibitors and 5-fluorouracil.
Lei Z; Tan IB; Das K; Deng N; Zouridis H; Pattison S; Chua C; Feng Z; Guan YK; Ooi CH; Ivanova T; Zhang S; Lee M; Wu J; Ngo A; Manesh S; Tan E; Teh BT; So JB; Goh LK; Boussioutas A; Lim TK; Flotow H; Tan P; Rozen SG
Gastroenterology; 2013 Sep; 145(3):554-65. PubMed ID: 23684942
[TBL] [Abstract][Full Text] [Related]
15. Integrated multi-omics analysis of ovarian cancer using variational autoencoders.
Hira MT; Razzaque MA; Angione C; Scrivens J; Sawan S; Sarker M
Sci Rep; 2021 Mar; 11(1):6265. PubMed ID: 33737557
[TBL] [Abstract][Full Text] [Related]
16. Single-cell triple omics sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in hepatocellular carcinomas.
Hou Y; Guo H; Cao C; Li X; Hu B; Zhu P; Wu X; Wen L; Tang F; Huang Y; Peng J
Cell Res; 2016 Mar; 26(3):304-19. PubMed ID: 26902283
[TBL] [Abstract][Full Text] [Related]
17. An integrated clinical-genomics approach identifies a candidate multi-analyte blood test for serous ovarian carcinoma.
Meinhold-Heerlein I; Bauerschlag D; Zhou Y; Sapinoso LM; Ching K; Frierson H; Bräutigam K; Sehouli J; Stickeler E; Könsgen D; Hilpert F; von Kaisenberg CS; Pfisterer J; Bauknecht T; Jonat W; Arnold N; Hampton GM
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):458-66. PubMed ID: 17255266
[TBL] [Abstract][Full Text] [Related]
18. Screening for genes associated with ovarian cancer prognosis.
Chang XH; Zhang L; Yang R; Feng J; Cheng YX; Cheng HY; Ye X; Fu TY; Cui H
Chin Med J (Engl); 2009 May; 122(10):1167-72. PubMed ID: 19493465
[TBL] [Abstract][Full Text] [Related]
19. IGF axis gene expression patterns are prognostic of survival in epithelial ovarian cancer.
Spentzos D; Cannistra SA; Grall F; Levine DA; Pillay K; Libermann TA; Mantzoros CS
Endocr Relat Cancer; 2007 Sep; 14(3):781-90. PubMed ID: 17914107
[TBL] [Abstract][Full Text] [Related]
20. Amplification of MDS1/EVI1 and EVI1, located in the 3q26.2 amplicon, is associated with favorable patient prognosis in ovarian cancer.
Nanjundan M; Nakayama Y; Cheng KW; Lahad J; Liu J; Lu K; Kuo WL; Smith-McCune K; Fishman D; Gray JW; Mills GB
Cancer Res; 2007 Apr; 67(7):3074-84. PubMed ID: 17409414
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]